ULURU Inc. Announces Poster Presentation of Dr. Gregory Bohn
24 October 2009 - 4:17AM
PR Newswire (US)
- Cost Benefits of Altrazeal(TM) Highlighted - Evidence of Reduced
Pain and Accelerated Healing Presented ADDISON, Texas, Oct. 23
/PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) today
announced that Gregory Bohn, M.D., FACS, Medical Director, Trinity
Wound Care and Hyperbaric Medicine, Bettendorf, Iowa, has presented
nine clinical posters at the 24th Annual "Clinical Symposium on
Advances in Skin and Wound Care" being held in San Antonio, Texas.
Highlights of the clinical experience presented by Dr. Bohn's
poster presentations include: -- A stagnated traumatic wound that
was treated with Altrazeal(TM) eliminated the need for a skin graft
procedure -- Using Altrazeal(TM) in combination with total contact
casts decreased "days to heal" from 41 days to 15 days in Wagner
grade 2 neuropathic diabetic foot ulcers -- Chronic venous stasis
ulcer patients that had not healed in 30 months after treatments
including skin graft and bioengineered skin graft healed after
treatment with Altrazeal(TM) Commenting on Altrazeal(TM), Dr.
Gregory Bohn stated, "Altrazeal(TM) can be a work horse in the
wound care field. I have seen dramatic clinical results on many
different types of problematic wounds. I have also found that
Altrazeal(TM) increases wound care dressing wear time which has
been instrumental in increasing patients' treatment compliance and
enabling costs to be constrained within Medicare monthly limits for
stomal and wound care supplies. Additionally, combining
Altrazeal(TM) with contact casts for Wagner grade 2 diabetic foot
ulcers has reduced our days to heal from 41 days to 15.2 days
representing a substantial cost savings and avoiding morbidity for
our diabetic patients." Also included in the poster presentations
by Dr. Bohn was evidence of the benefits of using Altrazeal(TM),
including: -- Reduction in pain and improvement in quality of life
-- Eliminated the need for patients to use oral narcotics to manage
pain -- Provides significant cost benefits -- Documented $1,260
monthly savings for a patient with a peristomal pyoderma -- Reduced
healing times for diabetic foot ulcer patients resulting in
significant savings -- Long wear time for Altrazeal(TM) allows
greater versatility in wound treatment and combination with other
treatments including contact casts Altrazeal(TM), a transforming
powder dressing which is produced using our patented Nanoflex(TM)
Technology, is suitable for exuding wounds such as burns,
abrasions, trauma, skin graft donor sites, surgical wounds and
chronic slow-healing wounds such as diabetic foot ulcers, pressure
ulcers and venous ulcers. Altrazeal(TM) is an innovative
breakthrough, designed for greater effectiveness in wound closure
by promoting an optimal moist wound healing environment, reducing
pain and enhancing patient comfort, ease of application and removal
and, in most cases, not requiring a secondary dressing. Renaat Van
den Hooff, President and CEO of ULURU Inc. further commented, "We
are delighted with the results achieved by Dr. Bohn and the
extensive supporting clinical evidence he has generated. The cost
effectiveness, accelerated healing, pain reduction and quality of
life evidence provides strong support for our sales and marketing
activities. This positive clinical evidence using Atlrazeal(TM)
includes many different wound types including diabetic foot ulcers,
venous ulcers, burns, chronic traumatic wounds and degenerative
skin conditions." About ULURU Inc.: ULURU Inc. is a specialty
pharmaceutical company focused on the development of a portfolio of
wound management and oral care products to provide patients and
consumers improved clinical outcomes through controlled delivery
utilizing its innovative Nanoflex(TM) Aggregate technology and
OraDisc(TM) transmucosal delivery system. For further information
about ULURU Inc., please visit our website at
http://www.uluruinc.com/. For further information about
Altrazeal(TM), please visit http://www.altrazeal.com/. This press
release contains certain statements that are forward-looking within
the meaning of Section 27a of the Securities Act of 1933, as
amended, including but not limited to statements made relating to
the benefits, effectiveness, success in wound healing, including
pain reduction and accelerated healing, clinical outcomes, and
suitability of Altrazeal(TM), pharmacoeconomic benefits and the
success of our clinical efforts. These statements are subject to
numerous risks and uncertainties, including but not limited to the
risk factors detailed in the Company's Annual Report on Form 10-K
for the year ended December 31, 2008, and other reports filed by us
with the Securities and Exchange Commission. Contact: Company
Renaat E. Van den Hooff President & CEO Terry K. Wallberg Vice
President & CFO (214) 905-5145 DATASOURCE: ULURU Inc. CONTACT:
Renaat E. Van den Hooff, President & CEO, or Terry K. Wallberg,
Vice President & CFO, both of ULURU Inc., +1-214-905-5145 Web
Site: http://www.uluruinc.com/ http://www.altrazeal.com/
Copyright